Meta-Analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer
Paz-Ares L, Zimmerman A, Ciuleanu T, Bunn P, San Antonio B, Denne J, Iturria N, John WJ, and Scagliotti G, Lung Cancer, 1/1/2017Treatment patterns and cost effectiveness of the first-line treatment of advanced nonsquamous non-small cell lung cancer in Medicare patients
Gildon DM, Kubisiak JM, Pohl GM, Ball DE, Gilden DE, John WJ, Wetmore S, and Winfree KB, J Med Oncol, 1/1/2016Patient-Reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer
Smyth E, Shen W, Bowman L, Peterson P, John WJ, Melemed A, and Liepa A, Health and Quality of Life Outcomes, 1/1/2016Analysis of pemetrexed plus carboplatin doublet safety profile in first line non-squamous non-small cell lung cancer (NSCLC) studies
Okamoto I, Schuette W, Stinchcombe T, Pereira J, Lui J, San Antonio B, John WJ, Chen J, and Zinner R, Curr Med Rev Opin, 1/1/2016Safety profiles of non-small cell lung cancer patients treated with pemetrexed plus carboplatin: A real world experience
Chen L, Goodloe R, Yan Y, John WJ, Chen J, and San Antonio B, Curr Med Rev Opin, 1/1/2016Adverse events in patients with advanced non-small cell lung cancer: Findings from IMS Oncology, a US Oncology electronic medical record
Chen L, San Antonio B, Swain JL, Mitchell L, John WJ, Akoub H, Michael J, Marmaduke DQ, and Yuer Y, Pharmacoepidemiology and Drug Safety, 1/1/2015PARAMOUNT: Descriptive subgroup analysis of final overall survival for the phase III study of maintenance pemetrexed vs placebo following induction treatment with peme...
Reck M, Paz-Ares L, de Marinis F, Molinier O, Sahoo TP, Laack E, John WJ, Zimmerman A, Visseren-Grul C, and Gridelli C, J Thorac Oncol, 1/1/2014Final efficacy and safety results of pemetrexed continuation maintenance in the elderly from the PARAMOUNT phase III study
Gridelli C, de Marinis F, Thomas M, Prabhash K, El Kouri C, Blackhall F, Bustin F, Pujol JL, John WJ, San Antonio B, Zimmerman A, Choudaki N, Visseren-Grul C, and Paz-..., J Thorac Oncol, 1/1/2014A comprehensive review of non-genetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small cell lung cancer
Carter GC, Barrett AM, Kaye JA, Liepa AM, Winfree KB, and John WJ, Cancer Manag Res, 1/1/2014Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately following induction treatment with pemetrexed plus cisplatin...
Paz-Ares L, de Martinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo T, Laack E, Reck M, Corral J, Melemed S, John W, Choudiak N, Zimmerman A, Visseren-..., J Clin Oncol, 1/1/2013PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carbo...
Patel JD, Socinski MA, Garon E, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM,Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Penn..., J Clin Oncol, 1/1/2013Indentifying the target NSCLC patient for maintenance therapy: An analysis from a placebo controlled phase III trial of maintenance pemetrexed
Obasaju C, Bowman L, Shen W, Wang P, John W, Winfree K, Nash-Smyth E, Broderwicz T, Belani C, Ann Oncol, 1/1/2013Maintenance Treatment: Results from a randomized phase III study of pemetrexed vs placebo
Belani CE, Brodowicz T, Ciuleanu TE, Krzakowski M, Yang SH, Franke F, Cucevic B, Madhavan J, Santoro A, Ramlau R< Liepa AM, Visseren-Grul C, Peterson P, John WJ, Zi..., Lancet Oncol, 1/1/2012PARAMOUNT: Phase III study of maintenance Pemetrexed plus best supportive care versus placebo plus best supportive care following induction treatment with pemetrexed p...
Paz-Ares L, de Martinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo T, Laack E, Reck M, Corral J, Melemed S, John W, Choudiak N, Zimmerman A, Visseren-..., Lancet Oncol, 1/1/2012Safety, resource use, and quality of life in PARAMOUNT: A phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanc...
Gridelli C, de Marinis F, Pujol J-L, Reck M, Ramlau R, Parente B, Pieters T, Middleton G, Winfree K, Melemed S, Zimmermann A, John W, Beyrer J, Chouski NVisseren-Grul ..., J Thor Oncol, 1/1/2012Maintenance pememtrexed plus best supportive care vs placebo plus best supportive care for non-small cell lung cancer: A randomized double-blind phase III study
Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Pete..., Lancet, 1/1/2009Phase III study of gemcitabine and cisplatin with or without aprinocasen an antisense oligonucleotide in patients with advanced stage non small cell lung cancer
Paz-Ares L, Doulliard JY, Koralewski P, Manegold C, Smit E, John WJ, Peterson P, Obasaju C, Lahn M, Gandara D, J Clin Oncol, 1/1/2006Pemetrexed and oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the NSABP foundation research program
Atkins J, Jacobs S, Wieand S, Smith R, John WJ, Colangelo L, Geyer C, Wolmark N, Clin Colorectal Cancer, 1/1/2005A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreas cancer
Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, Zimmerman A, John WJ, von Hoff D, Arning M, Kindler H, Ann Oncol, 1/1/2005Preoperative chemoradiation in fixed distal rectal cancer: Dose time factors for pathological complete response
Mohiuddin M, Regine WF John WJ, Hagihara PF, McGrath PC, Kenady DE, Marks G, Int J Radiation Oncology Biol Phys, 1/1/2000Results of high-dose intra-arterial (IA) cisplatin and concurrent hyperfractionated radiation therapy (HFX-RT) in patients with high volume unfavorable squamous cell c...
Regine WF, Valentino J, John WJ, Storey G, Patel P, Sloan D, Kenady D, Pulmano C, Abner J, Mohiuddin M, Head Neck, 1/1/2000Activity of MTA (LY 231514) in patients with advanced colorectal cancer: Report of a phase II study
John WJ, Clark J, Burris H, Picus J, Schulman L, Thornton D, Loehrer P, Cancer, 1/1/2000A phase II trial of multi-targeted antifolate (MTA) (LY231514) in patients with unresectable pancreatic cancer
Miller KD, Loehrer PJ, Picus J, Blanke C, John WJ, Clark J, Schulman LN, Burris H, Thornton D, Ann Oncol, 1/1/2000Clinical and immune responses in surgically resected colorectal cancer (CRC) patients treated with anti-idiotype antigen (CEA) with or without fluorouracil (5-FU)
Foon KA, John WJ, Chakraborty M, Garrison J, Bard M, Bhattachary-Chatterjee M, J Clin Oncol, 1/1/1999Adjuvant therapy for pancreas cancer: Current status
Regine WF, John WJ and Mohiuddin M, Frontiers in Bioscience, 1/15/1998- Join now to see all
University of Kentucky College of MedicineFellowship, Gastroenterology, 1988 - 1989
University of Kentucky College of MedicineClass of 1981
University of KentuckyB.G.S., Medicine, 1974 - 1978
KY State Medical License 1982 - 2025
MD State Medical License 1988 - 1988
